Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Neuroblastoma 2Neoplasms 2Neoplasm Metastasis 2Melanoma 2Thyroid Carcinoma, Anaplastic 1Pancreatic Neoplasms 1Noonan Syndrome 6 1Non-small Cell Lung Cancer Harboring ROS1 Rearrangement 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Hematologic Neoplasms 1Glioblastoma 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma 1Brain Neoplasms 1ALK-positive Non-small Cell Lung Cancer 1

Interventions

Cyclophosphamide 48fludarabine phosphate 32Peripheral Blood Stem Cell Transplantation 32Whole-Body Irradiation 26Etoposide 23Mycophenolic Acid 22Rituximab 20Filgrastim 18Doxorubicin 18Vincristine 16Cyclosporine 16Busulfan 16Tacrolimus 15Prednisone 15Methotrexate 13Melphalan 13Antilymphocyte Serum 12Cytarabine 11Radiotherapy 10Carboplatin 10Bortezomib 9romidepsin 8Ifosfamide 8Cord Blood Stem Cell Transplantation 8Methylprednisolone 7Lenalidomide 7Flow Cytometry 7Brentuximab Vedotin 7Sirolimus 6Everolimus 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Large-Cell, Anaplastic × ceritinib × Clear all
NCT02729961 2019-10-10

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

University of Washington

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡